Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.

Oral noninferior to intravenous sedation for cataract surgery

04 Sep 2019

Oral sedation is noninferior to intravenous sedation for cataract surgery in terms of patient satisfaction in a diverse patient population, a study has shown.

“The use of oral sedation in cataract surgery has been suggested as a cost- and space-saving measure, potentially allowing the transition of some patients from an operating to procedure room or office-based setting,” the authors said.

A total of 85 patients (mean age, 65.7 years; 49.4 percent men; standard deviation, 9.5 years) were included. The mean satisfaction score was 5.34±0.63 (range, 3.75–6) in the oral sedation group and 5.40±0.52 (range, 4–6) in the intravenous group.

Noninferiority of oral sedation was shown by an a priori noninferiority margin of 0.5 and a difference in mean scores between the two groups of 0.06 (1-tailed 95 percent CI, –infinity to 0.27; p=0.0004). The two groups also had similar surgeon and anaesthesia provider satisfaction.

Intraoperative complications occurred in 16.7 percent and 9.3 percent in the oral and intravenous groups (difference, 7.4, –6.9 to 21.6 percent; p=0.31), respectively. The only major intraoperative complication, a posterior capsular tear, occurred in the intravenous group.

Supplemental intravenous sedation was given to eight patients (19.0 percent) in the oral group and three (7.0 percent) in the intravenous group (difference, 12.1 percent, –2.0 to 26.2 percent; p=0.097).

This prospective, randomized, double-masked clinical trial included a volunteer sample of patients aged ≥18 years from diverse backgrounds scheduled for cataract surgery. Excluded were those who were allergic to benzodiazepines, aged >70 years with a failed delirium screening questionnaire, pregnant or nursing, using a medication inhibiting cytochrome 450 3A, or intoxicated on the day of surgery.

Patients were randomly assigned to receive either oral triazolam with intravenous placebo or intravenous midazolam with oral placebo before surgery. Patient satisfaction, measured by a survey administered on postoperative day 1, was the primary outcome. Secondary outcomes included surgeon and anaesthesia provider satisfaction, need for supplemental anaesthesia, and surgical complications.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.